CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($) $ in Thousands	Common Stock Gilead Stock Purchase Agreement	Common Stock Private Placement	Common Stock At-the-Market Offerings	Common Stock	Additional Paid-in Capital Gilead Stock Purchase Agreement	Additional Paid-in Capital Private Placement	Additional Paid-in Capital At-the-Market Offerings	Additional Paid-in Capital	Accumulated Deficit	Gilead Stock Purchase Agreement	Private Placement	At-the-Market Offerings	Total
Beginning balance at Dec. 31, 2022				$ 3				$ 354,752	$ (249,108)				$ 105,647
Beginning balance (in shares) at Dec. 31, 2022				27,425,447
Stockholders' Deficit
Issuance of common stock under employee stock purchase plan								140					140
Issuance of common stock under employee stock purchase plan (in shares)				68,929
Vesting of restricted common stock (in shares)				31,793
Exercise of stock options								8					8
Exercise of stock options (in shares)				2,757
Stock-based compensation expense								5,452					5,452
Net Income (Loss)									(58,749)				(58,749)
Ending balance at Sep. 30, 2023				$ 3				360,352	(307,857)				52,498
Ending balance (in shares) at Sep. 30, 2023				27,528,926
Beginning balance at Jun. 30, 2023				$ 3				358,483	(291,109)				67,377
Beginning balance (in shares) at Jun. 30, 2023				27,518,895
Stockholders' Deficit
Vesting of restricted common stock (in shares)				7,598
Exercise of stock options								8					8
Exercise of stock options (in shares)				2,433
Stock-based compensation expense								1,861					1,861
Net Income (Loss)									(16,748)				(16,748)
Ending balance at Sep. 30, 2023				$ 3				360,352	(307,857)				52,498
Ending balance (in shares) at Sep. 30, 2023				27,528,926
Beginning balance at Dec. 31, 2023				$ 3				362,336	(325,512)				36,827
Beginning balance (in shares) at Dec. 31, 2023				27,607,646
Stockholders' Deficit
Issuance of common stock and prefunded warrants, net of issuance costs					$ 7,605	$ 9,908				$ 7,605	$ 9,908
Issuance of common stock and prefunded warrants, net of issuance costs (in shares)	7,345,473	1,953,125
Issuance of common stock in connection with at-the-market offerings, net of issuance costs			$ 1				$ 6,824					$ 6,825
Issuance of common stock in connection with at-the-market offerings, net of issuance costs (in shares)			7,000,000									7,000,000
Issuance of common stock under employee stock purchase plan								34					34
Issuance of common stock under employee stock purchase plan (in shares)				38,998
Vesting of restricted common stock (in shares)				5,617
Exercise of stock options								5					$ 5
Exercise of stock options (in shares)				7,215									7,215
Stock-based compensation expense								4,918					$ 4,918
Net Income (Loss)									(45,148)				(45,148)
Ending balance at Sep. 30, 2024				$ 4				391,630	(370,660)				20,974
Ending balance (in shares) at Sep. 30, 2024				43,958,074
Beginning balance at Jun. 30, 2024				$ 4				390,052	(356,640)				33,416
Beginning balance (in shares) at Jun. 30, 2024				43,951,922
Stockholders' Deficit
Issuance of common stock in connection with at-the-market offerings, net of issuance costs (in shares)												0
Exercise of stock options								4					4
Exercise of stock options (in shares)				6,152
Stock-based compensation expense								1,574					1,574
Net Income (Loss)									(14,020)				(14,020)
Ending balance at Sep. 30, 2024				$ 4				$ 391,630	$ (370,660)				$ 20,974
Ending balance (in shares) at Sep. 30, 2024				43,958,074